

International Headquarters
 2150 St. Elzéar Blvd. West
 Laval, Quebec H7L 4A8
 Phone: 514.744.6792
 Fax: 514.744.6272

Contact Information:

Elif McDonald
 elif.mcdonald@valeant.com
 514-856-3855
[877-281-6642 \(toll free\)](tel:877-281-6642)

Media:
 Renée Soto
 or
 Chris Kittredge/Jared Levy
 Sard Verbinnen & Co.
 212-687-8080

VALEANT ANNOUNCES 2017 ANNUAL MEETING RESULTS

LAVAL, QUEBEC, May 3, 2017 — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (“Valeant” or the “Company”) announced today the election of the ten directors nominated at its 2017 annual meeting of shareholders held on May 2, 2017. The detailed results of the vote for the election of directors are set out below:

Name	For	Withheld	Broker Non-Votes
Richard U. DeSchutter	123,623,109	5,319,736	98,872,954
Dr. Frederic N. Eshelman	126,125,069	2,817,776	98,872,954
D. Robert Hale	123,127,211	5,815,634	98,872,954
Dr. Argeris (Jerry) N. Karabelas	123,529,948	5,412,897	98,872,954
Sarah B. Kavanagh	126,292,442	2,650,403	98,872,954
Joseph C. Papa	123,983,101	4,959,744	98,872,954
Robert N. Power	125,649,938	3,292,907	98,872,954
Russel C. Robertson	126,590,227	2,352,618	98,872,954
Thomas W. Ross, Sr.	126,166,299	2,776,546	98,872,954
Amy B. Wechsler, M.D.	123,473,243	5,469,602	98,872,954

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation and an annual frequency of advisory votes on the compensation of our named executive as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2018 annual meeting of shareholders.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

###